NOVATO, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) will host an Investor Day on Thursday, April 30, 2015, from 8:30 a.m. to 12:00 p.m. EDT (5:30 a.m. to 9:00 a.m. PDT) in New York City. Julie Anne Smith, President and Chief Executive Officer, and other members of the Raptor management team will provide a comprehensive update of commercial and clinical operations. In addition, notable industry experts in cystinosis, Huntington's disease, pediatric nonalcoholic steatohepatitis (pNASH) and mitochondrial diseases will discuss their perspective of Raptor Pharmaceutical's existing product and pipeline of drug candidates.
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Raptor's website at www.raptorpharma.com beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
About Raptor Pharmaceutical
Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU. A request for orphan designation for Leigh syndrome has been submitted to the FDA. Raptor holds intellectual property for the use of cysteamine in HD and other neurodegenerative disorders including Parkinson's disease and Rett syndrome. For additional information, please visit www.raptorpharma.com.